Drugs / Oka strain varicella attenuated live vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06614816 | Feb 2019 → Jul 2021 | chickenpox | Southeast University, China | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oka strain varicella attenuated live vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06614816 ↗ |
| Known as | VarV | “The test group received the freeze-dried live attenuated VarV developed by Beijing Minhai Biotechnology Co., LTD., which are derived from the Oka strain, cultured and harvested...” NCT06614816 ↗ |
| Modality | Vaccine | “Live Attenuated Varicella Vaccine” NCT06614816 ↗ |
| Route | Subcutaneous | “lyophilized powder, subcutaneous injection” NCT06614816 ↗ |